SOURCE-LINKED STUDY SUMMARY
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.
Abstract summarizedQuality not appraised
- What was studied
- Two randomized OSA subtrials tested retatrutide versus placebo, nested within larger phase 3 trials.
- Who / model studied
- Adults with overweight/obesity and moderate-to-severe sleep apnea: 243 without and 448 with type 2 diabetes.
- Studied dose & schedule
- Subcutaneous retatrutide 4, 9 or 12 mg once weekly versus placebo for 80 weeks; doses describe the study.
- What the study found
- At 9 mg, placebo-adjusted AHI differences were −24.4 events/hour (95% CI −34.1 to −14.7) without diabetes and −14.4 (−21.6 to −7.2) with diabetes, using the hybrid estimand. Corresponding intention-to-treat differences were −24.7 and −13.9. Gastrointestinal events were most common.
- Limitations & context
- Abstract-based assessment; detailed safety counts unavailable. Companion analyses share participants with the basket trials. This was not a head-to-head comparison with another drug. Publisher and indexed publication dates differ by one day.
Read summary source ↗ · Prepared 10/28/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2611477